Get the Stockscreener App
4.60
0.00%
0.00
Immatics N V stock is traded at $4.60, with a volume of 1.73M.
It is up +0.00% in the last 24 hours and down -14.81% over the past month.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
See More
Previous Close:
$4.60
Open:
$4.64
24h Volume:
1.73M
Relative Volume:
2.09
Market Cap:
$559.13M
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-3.5393
EPS:
-1.2997
Net Cash Flow:
$-13.78M
1W Performance:
-8.91%
1M Performance:
-14.81%
6M Performance:
-60.14%
1Y Performance:
-61.70%
1-Day Range:
$4.48
$4.6874
1-Week Range:
$4.48
$5.21
52-Week Range:
$4.48
$13.77
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
4.60 | 559.13M | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register
Financial Metrics Unveiled: Immatics N.V (IMTX)’s Key Ratios in the Spotlight - The Dwinnex
Immatics (NASDAQ:IMTX) Sets New 1-Year Low – What’s Next? - Defense World
(IMTX) Trading Signals - Stock Traders Daily
Immatics (NASDAQ:IMTX) Reaches New 1-Year LowHere's What Happened - MarketBeat
abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX) - MarketBeat
Immatics (NASDAQ:IMTX) Trading Down 4.7% – What’s Next? - Defense World
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance
Immatics N.V (IMTX): An Important Analyst Insights - Stocks Register
Financial Metrics Check: Immatics N.V (IMTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowTime to Sell? - MarketBeat
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
It is Poised to be a Bull Market for Immatics N.V (IMTX) - SETE News
Immatics N.V (IMTX) Becoming More Attractive for Investors - Knox Daily
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in January - MarketBeat
Immatics (NASDAQ:IMTX) Hits New 52-Week LowShould You Sell? - MarketBeat
Immatics N.V (IMTX) Volatility Hits 4.72% – Here Is What You Should Do - Stocks Register
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Immatics (NASDAQ:IMTX) - Defense World
Brokers Offer Predictions for Immatics FY2025 Earnings - ETF Daily News
Cantor Fitzgerald Predicts Immatics FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Immatics FY2025 Earnings - MarketBeat
Is Immatics N.V. (IMTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in December - MarketBeat
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Immatics (NASDAQ:IMTX) Shares Down 3.9%What's Next? - MarketBeat
Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround - Yahoo Finance
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price - Simply Wall St
Immatics N.V.: Considering More Engineered T Cells For Cancer (NASDAQ:IMTX) - Seeking Alpha
IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com
Analyzing Immatics (NASDAQ:IMTX) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
How to Take Advantage of moves in (IMTX) - Stock Traders Daily
State Street Corp Grows Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) & Achilles Therapeutics (NASDAQ:ACHL) Financial Survey - Defense World
ZTS: 3 Healthcare Innovators with Analyst-Endorsed Upside - StockNews.com
(IMTX) Technical Data - Stock Traders Daily
Immatics (NASDAQ:IMTXW) Stock Price Down 0.7% – Time to Sell? - Defense World
Comparing Calidi Biotherapeutics (NYSE:CLDI) & Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Hits New 12-Month LowWhat's Next? - MarketBeat
Immatics (NASDAQ:IMTX) Sees Significant Increase in Short Interest - MarketBeat
(IMTX) Technical Pivots with Risk Controls - Stock Traders Daily
Immatics (NASDAQ:IMTX) Trading Down 4.2%What's Next? - MarketBeat
Immatics Faces Termination of Key Collaboration with Bristol Myers Squibb - TipRanks
Immatics (NASDAQ:IMTX) Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):